Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia

Akihisa Yumoto, Fukushima Kusano Kengo, Kazufumi Nakamura, Katsushi Hashimoto, Motokuni Aoki, Ryuichi Morishita, Yasufumi Kaneda, Tohru Ohe

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined the anti-arrhythmic effect of HGF gene therapy in rat acute and old myocardial infarction models. Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemagglutinating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the myocardium fourteen days before programmed pacing. Ventricular fibrillation (VF) was induced by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF gene therapy (P < 0.01). Histological analyses revealed that the number of vessels in the ischemic border zone was greatly increased after HGF gene injection. These findings revealed that HGF gene therapy has an anti-arrhythmic effect after myocardial ischemia. Copyright

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalActa medica Okayama
Issue number3
Publication statusPublished - Jun 2005


  • HGF (hepatocyte growth factor)
  • HVJ (hemagglutinating virus of Japan)
  • Ischemia
  • Ventricular arrhythmia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia'. Together they form a unique fingerprint.

Cite this